Helene M. Finney - Concepedia

Author

Helene M. Finney

UCB Pharma (United Kingdom)

Also Known As

Finney, H, H A Finney, H Finney, H. Finney, H.M. Finney, Helene Finney, Helene M Finney, Helene M. Finney

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

UCB Pharma (United Kingdom)University College London University of Milano-Bicocca Centre Léon Bérard CTI BioPharma (United Kingdom)

About

Helene M. Finney is an author at UCB Pharma (United Kingdom) specializing in immunology, medicine, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.1K
2	Immunology	8	8	1.1K
3	Cell Biology	5	5	865
4	Allergy	3	3	572
5	Cellular Therapies	1	1	17

Helene M. Finney

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product Helene M. Finney, Alastair D. G. Lawson, Christopher Bebbington, The Journal of Immunology	1998	532
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain Helene M. Finney, Arne N. Akbar, Alastair D. G. Lawson The Journal of Immunology T-regulatory CellImmunologyImmune RegulationImmunologic MechanismPrimary T Cells	2004	450
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection Abhishek Das, Matthew Hoare, Nathan Davies, The Journal of Experimental Medicine	2008	254
The Loss of Telomerase Activity in Highly Differentiated CD8+CD28−CD27− T Cells Is Associated with Decreased Akt (Ser473) Phosphorylation Fiona J. Plunkett, Ornella Franzese, Helene M. Finney, The Journal of Immunology Signal TransductionCell RegulationCd3 ZetaTelomerase ActivityMedicine	2007	214
Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors Virna Marin, Irene Pizzitola, Valentina Agostoni, Haematologica	2010	125
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration Bryan Smith, Rocío Lledó‐García, Kate L. Dixon, mAbs Immunocytochemical TechniqueImmunotoxicologyAntibody IsolationImmunologyImmunotherapeutics	2018	110
PDGFβ Receptor Blockade Inhibits Intimal Hyperplasia in the Baboon Charles E. Hart, Larry W. Kraiss, Selina Vergel, Circulation	1999	101
<i>In Vitro</i>and<i>In Vivo</i>Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msup><mml:mrow><mml:mtext>CD</mml:mtext><mml:mn mathvariant="bold">33</mml:mn></mml:mrow><mml:mrow><mml:mo mathvariant="bold">+</mml:mo></mml:mrow></mml:msup></mml:math>Acute Myeloid Leukemia Aurélie Dutour, Virna Marin, Irene Pizzitola, Advances in Hematology Mn Mathvariant=T-regulatory CellImmunologyImmunotherapyMo Mathvariant=	2012	99
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy DJ King, Pari Antoniw, JR Adair, British Journal of Cancer Translational MedicineHumanised A33 ImmunoconjugatesRadiation TherapyMedicineImmunology	1995	88
Splice variants of human FOXP3 are functional inhibitors of human CD4<sup>+</sup> T‐cell activation Emma Smith, Helene M. Finney, Andrew Nesbitt, Immunology T-regulatory CellImmune RegulationImmunologyPathologyImmunologic Mechanism	2006	85

Page 1